64.8 F
Laguna Hills
Thursday, Jun 30, 2022
-Advertisement-
-Advertisement-

Edwards Pauses Some New Enrollments

- Advertisement -

Edwards Lifesciences Corp. won’t start new enrollments in some current clinical trials for mitral and tricuspid valve replacement products.

With hospitals focusing on coronavirus patients, some elective work is being deferred.

The Irvine medical device maker, OC’s largest public company by market cap, spends about $200 million a quarter on research and development.

Edwards shares (NYSE: EW) traded down about 1.5% Monday to a $40 billion market cap.

Go here for more updates on how OC companies are responding to coronavirus.

For ongoing, in-depth coverage of coronavirus effects on OC businesses, see the Monday print edition of the Business Journal.

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-